By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) To Participate In March 2015 Investor Conferences 2/20/2015 7:52:57 AM
Emergent BioSolutions (EBS) Announces Primary Endpoints Met In Pivotal Study Supporting Licensure Of Building 55 2/13/2015 7:41:26 AM
Emergent BioSolutions (EBS) To Release Fourth Quarter And Full Year 2014 Financial Results And Conduct A Conference Call On March 5, 2015 2/12/2015 7:45:59 AM
Emergent BioSolutions (EBS)'s $60 Million Expansion to Double Current Space and Create 158 New Jobs 2/4/2015 6:51:53 AM
Emergent BioSolutions (EBS) Announces Preliminary 2014 Financial Results And Provides 2015 Financial Outlook 1/12/2015 7:16:24 AM
Emergent BioSolutions (EBS) To Participate In January 2015 Investor Conferences 1/7/2015 10:15:38 AM
Emergent BioSolutions (EBS) Expands Biodefense Franchise; Acquires Portfolio Of Broad Spectrum Antibiotics 12/17/2014 7:33:24 AM
Evolva A/S Unloads EV-035 Series To Emergent BioSolutions (EBS) For $70.5 Million Plus 12/17/2014 6:49:42 AM
Emergent BioSolutions (EBS) To Webcast Presentation At 25th Annual Oppenheimer Healthcare Conference 11/24/2014 1:48:45 PM
Drugmakers Like Johnson & Johnson (JNJ), Emergent BioSolutions (EBS), And Mapp Biopharmaceutical Stand To Gain Ebola Contracts Worth $2 Billion 11/11/2014 6:48:25 AM